Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2025Ukraïnsʹkij žurnal medicini bìologìï ta sportu

Modern strategies for lipid-lowering therapy in patients with ischaemic heart failure and concomitant metabolic pathology

View Full Paper
Ask AI
Bookmark
Share

Authors

KBKateryna Borovyk

Discussion

Loading...

Member takes

Overview

Analysis shows lipid-lowering therapy improves LDL-C levels in patients with chronic heart failure and obesity, suggesting combined treatment may be more effective.

Key Points

  • Combined therapy with rosuvastatin and ezetimibe achieved target LDL-C levels in 95.5% of patients, demonstrating significant effectiveness.
  • In the study, 225 patients with ischaemic chronic heart failure were evaluated, revealing that higher adherence rates improve therapy outcomes.
  • Assessment using lipid-lowering medication highlighted that rosuvastatin monotherapy was only partially effective in achieving target LDL-C levels.
  • Findings support the necessity for individualized treatment approaches for dyslipidaemia in patients with chronic heart failure.

Cite This Study

Kateryna Borovyk (2025) studied this question.

synapsesocial.com/papers/68af7c8d7567bf4f94ff3e33https://doi.org/10.63341/ujmbs/2.2025.37
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Analysis of Methods for Normalizing Lipid Profile and Blood Pressure in Patients with Chronic Coronary Syndromes2025
  2. 2Adding Ezetimibe to High-Intensity Statin at the Time of Admission in Patients With Acute Coronary Syndrome: Results From the Optimization of Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome (OLA) Study2025
  3. 3Current and Future Perspectives of LDL-C Lowering Therapies 20262026 · 2 citations
  4. 4Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry2025 · 1 citations
  5. 5Predicting LDL-cholesterol reduction variability on statin–ezetimibe therapy: insights from “Jena auf Ziel”2026